References
- Urquhart L. Top drugs and companies by sales in 2018. Nat Rev Drug Discov. 2019. doi:https://doi.org/10.1038/d41573-019-00049-0.
- Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67:95–11. doi:https://doi.org/10.1016/j.molimm.2015.01.003.
- Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9:182–212. doi:https://doi.org/10.1080/19420862.2016.1268307.
- Batista FD, Neuberger MS. Affinity dependence of the B cell response to antigen: A threshold, a ceiling, and the importance of off-rate. Immunity. 1998;8:751–59. doi:https://doi.org/10.1016/S1074-7613(00)80580-4.
- Nuñez-Prado N, Compte M, Harwood S, Álvarez-Méndez A, Lykkemark S, Sanz L, Alvarez-Vallina L. The coming of age of engineered multivalent antibodies. Drug Discov Today. 2015;20:588–94.
- Cuesta ÁM, Sainz-Pastor N, Bonet J, Oliva B, Álvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 2010;28:355–62. doi:https://doi.org/10.1016/j.tibtech.2010.03.007.
- Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, Clark R, Johnston J, Shelton A, Mai E, et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Sci Transl Med. 2018;10:eaat5775. doi:https://doi.org/10.1126/scitranslmed.aat5775.
- Fan C-Y, Huang -C-C, Chiu W-C, Lai -C-C, Liou -G-G, Li H-C, Chou M-Y. Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold. Faseb J. 2008;22:3795–804. doi:https://doi.org/10.1096/fj.08-111484.
- Zhu X, Wang L, Liu R, Flutter B, Li S, Ding J, Tao H, Liu C, Sun M, Gao B, et al. COMBODY: one-domain antibody multimer with improved avidity. Immunol Cell Biol. 2010;88:667–75. doi:https://doi.org/10.1038/icb.2010.21.
- Liu M, Wang X, Yin C, Zhang Z, Lin Q, Zhen Y, Huang H. Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb. Biochem J. 2007;406:237–46. doi:https://doi.org/10.1042/BJ20070149.
- Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem. 2008;77:557–82. doi:https://doi.org/10.1146/annurev.biochem.77.060806.091238.
- Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 1995;267:1498–502. doi:https://doi.org/10.1126/science.7878469.
- Kraiss S, Quaiser A, Oren M, Montenarh M. Oligomerization of oncoprotein p53. J Virol. 1988;62:4737–44. doi:https://doi.org/10.1128/JVI.62.12.4737-4744.1988.
- Rheinnecker M, Hardt C, Ilag LL, Kufer P, Gruber R, Hoess A, Lupas A, Rottenberger C, Plückthun A, Pack P, et al. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. J Immunol. 1996;157:2989–97.
- Willuda J, Kubetzko S, Waibel R, Schubiger PA, Zangemeister-Wittke U, Plunckthun A. Tumor targeting of Mono-, Di-, and tetravalent anti-p185HER-2 miniantibodies multimerized by self-associating peptides. J Biol Chem. 2001;276:14385–92. doi:https://doi.org/10.1074/jbc.M011669200.
- Wu AM, Tan GJ, Sherman MA, Clarke P, Olafsen T, Forman SJ, Raubitschek AA. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng. 2001;14:1025–33. doi:https://doi.org/10.1093/protein/14.12.1025.
- AbbVie. Humira (adalimumab) injection, for subcutaneous use; 2015. http://www.rxabbvie.com/pdf/humira.pdf.
- Beghein E, Gettemans J. Nanobody technology: A versatile toolkit for microscopic imaging, protein-protein interaction analysis, and protein function exploration. Front Immunol. 2017;8:1–14. doi:https://doi.org/10.3389/fimmu.2017.00771.
- Reddy SP, Shah VV, Lin EJ, Wu JJ. Etanercept. In: Wu J, Feldman S, Lebwohl M, editors. Therapy for severe psoriasis. Philadelphia (PA): Elsevier. 2016. p. 83–96.
- DiPaola M, Li J, Stephens E. Development of biosimilars: analysis of etanercept glycosylation as a case study. J Bioanal Biomed. 2013;5:180–86. doi:https://doi.org/10.4172/1948-593X.1000096.
- Putnam CD, Hammel M, Hura GL, Tainer JA. X-ray solution scattering (SAXS) combined with crystallography and computation: defining accurate macromolecular structures, conformations and assemblies in solution. Q Rev Biophys. 2007;40(3):191–285. doi:https://doi.org/10.1017/S0033583507004635.
- Kikhney AG, Svergun DI. A practical guide to small angle X-ray scattering (SAXS) of flexible and intrinsically disordered proteins. FEBS Lett. 2015;589:2570–77. doi:https://doi.org/10.1016/j.febslet.2015.08.027.
- Chen X, Zaro JL, Shen W-C. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013;65:1357–69. doi:https://doi.org/10.1016/j.addr.2012.09.039.
- Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986;95:99–105. doi:https://doi.org/10.1016/0022-1759(86)90322-4.
- Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer. 2007;109:170–79. doi:https://doi.org/10.1002/cncr.22402.
- Lim KJ, Lee SJ, Kim S, Lee SY, Lee MS, Park YA, Choi EJ, Lee EB, Jun HK, Cho JM, et al. Comparable immune function inhibition by the infliximab biosimilar CT-P13: implications for treatment of inflammatory bowel disease. J Crohns Colitis. 2017;11:593–602. doi:https://doi.org/10.1093/ecco-jcc/jjw183.
- Abraham E, Anzueto A, Gutierrez G, Tessler S, Pedro GS, Wunderink R, Nogare AD, Nasraway S, Berman S, Cooney R, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet. 1998;351:929–33. doi:https://doi.org/10.1016/S0140-6736(05)60602-2.
- Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332:323–27. doi:https://doi.org/10.1038/332323a0.
- Svergun DI. Restoring low resolution structure of biological macromolecules from solution scattering using simulated annealing. Biophys J. 1999;76:2879–86. doi:https://doi.org/10.1016/S0006-3495(99)77443-6.
- Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr Sect D Biol Crystallogr. 2010;66:486–501. doi:https://doi.org/10.1107/S0907444910007493.
- Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera - A visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–12. doi:https://doi.org/10.1002/jcc.20084.